GDU5 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
GDU5 antibody; At5g24920 antibody; F6A4.130Protein GLUTAMINE DUMPER 5 antibody
Target Names
GDU5
Uniprot No.

Target Background

Function
GDU5 Antibody targets a protein that is likely a subunit of an amino acid transporter. This protein plays a crucial role in regulating amino acid metabolism by stimulating amino acid export through the activation of non-selective amino acid facilitators.
Database Links

KEGG: ath:AT5G24920

STRING: 3702.AT5G24920.1

UniGene: At.54984

Protein Families
GLUTAMINE DUMPER 1 (TC 9.B.60) family
Subcellular Location
Membrane; Single-pass membrane protein.
Tissue Specificity
Expressed in the vascular tissues. Also detected in guard cells.

Q&A

Advanced Research Questions

What experimental strategies resolve contradictory findings in anti-ganglioside antibody pathogenicity studies?

Three evidence synthesis approaches from recent studies:

A. Glycolipid complex profiling
Combinatorial arrays testing 15 glycolipids + 1 phospholipid complexes identified:

  • 92.6% seropositivity in GBS vs. 4.4% in controls

  • Anti-GQ1b:GM4 complexes associated with 40% faster recovery (HR=1.4, p=0.02)

B. Epitope spreading analysis
Longitudinal serum sampling reveals:

  • 39.6% cross-reactivity among anti-ganglioside antibodies

  • Antibody clusters persist ≥6 months post-onset in 22% of patients

C. Functional validation
Adoptive transfer models demonstrate:

  • IgG Fc galactosylation status modulates macrophage activation (p<0.001)

  • Mannose-glycan recognition required for inflammasome activation (NF-κB/CARD9 pathway)

How can antibody glycosylation patterns improve prognostic models?

Recent advancements integrate:

Glycosylation FeaturePrognostic ValueMethodology
IgG1/2 agalactosylation6-year preclinical CD prediction MALDI-TOF MS glycan profiling
FcγR-binding capacityDistinguishes pathogenic vs benignSurface plasmon resonance

Implementation challenges:

  • Requires standardization of glycoanalytical platforms (CV >15% inter-lab)

  • Combines poorly with existing Erasmus GBS Outcome Score (ΔAUC=0.03)

Technical Validation Framework

Experimental Confounders in Anti-Ganglioside Research

VariableControl MethodStudy Example
Autoantibody decayWeekly serial sampling for 8 weeks42% IgM titer drop by week 4
Cross-reactive epitopesPre-adsorption with C. jejuni lysate68% signal reduction
Complement interferenceHeat inactivation at 56°C ×30 minRestores neural binding

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.